Nicholas Stoycheff is a Nephrology physician. OpenAlex indexes 8 publications with 299 citations (h-index 6).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
5775 N Meadows Dr Ste D
Grove City, OH 431237300
Telephone
614-224-4200Provider last certified this registry record 20 May 2020.
Industry payments
2 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Becton, Dickinson and CompanyProgram year20251 payment
- AstraZeneca Pharmaceuticals LPProgram year20211 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
67.5%Beta blocker18.2%Carvedilol86%Metoprolol Succinate14%Part D<11 patientsCalcium channel blocker13.2%Amlodipine Besylate70%Nifedipine Er30%Part D<11 patients+ 8 more classes in this area
Other
17%Phosphate Binder10.4%Sevelamer Carbonate100%Part D≥14 patientsDrugs for treatment of hyperkalemia and hyperphosphatemia6.6%Velphoro100%Part D<11 patientsMetabolism & gastrointestinal
10.1%Vitamin D3 Analog10.1%Calcitriol100%Part D≥15 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Early Change in Proteinuria as a Surrogate End Point for Kidney Disease Progression: An Individual Patient Meta-analysis
American Journal of Kidney Diseases
2014 - Original Investigation Early Change in Proteinuria as a Surrogate End Point for Kidney Disease Progression: An Individual Patient Meta-analysis2014
- Nephrotic Syndrome in Diabetic Kidney Disease: An Evaluation and Update of the Definition
American Journal of Kidney Diseases
2009
Similar KOLs
Other experts from the same institution or the same specialty.
Giuseppe Remuzzi
Mario Negri Institute for Pharmacological Research
Marcello Tonelli
University of Calgary
Johan Ärnlöv
Dalarna University
Juan Jesús Carrero
Danderyds sjukhus
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”